JhanelleEGrayMD

Physician

Overview of Dr. Gray

Dr. Jhanelle Gray is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Weill Cornell Medicine and has been in practice 16 years. Dr. Gray accepts several types of health insurance, listed below. She is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
Moffitt Cancer Center
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(813) 547-6383

Fax+1 813-745-3027
Is this information wrong?

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Weill Cornell MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2004 - 2025
NY State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers Start of enrollment: 2008 Nov 01
Completed
Phase 1
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
Completed
Phase 1, Phase 2
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Start of enrollment: 2013 Dec 30
Completed
Phase 1
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Dec 31
Completed
Phase 1
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Mar 22
Active, not recruiting
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Start of enrollment: 2017 Dec 20
Completed
Phase 1, Phase 2
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Start of enrollment: 2018 Feb 02
Active, not recruiting
Phase 1, Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
Active, not recruiting
Phase 3
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Start of enrollment: 2015 Oct 30
Completed
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W Redman, Hong Chen, Ganiraju C Manyam, Gayatri Kumar, Jianhua Zhang, Xingzhi Song, Ros...> ;Clinical Cancer Research. 2024 Apr 15
HSR24-162: Treatment Patterns in Surgically Resected NSCLC Since the Introduction of Immuno-Oncology Agents.
Daniel Simmons, Lu Zou, Yahan Zhang, Wale Oyebanji, Tiernan Mulrooney, Jhanelle E Gray> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer.
Lancia Darville, Stephanie Hogue, Julie E Hallanger Johnson, Youngchul Kim, Alexis Bailey, Lary A Robinson, Yumeng Zhang, Trevor Rose, Jhanelle E Gray> ;Cancers. 2024 Mar 14
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer.
Aakash Desai, Tadana A Vázquez, Keishla M Arce, Marcelo Corassa, Philip C Mack, Jhanelle E Gray, Bruna Pellini> ;Cancers. 2024 Feb 26
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...
D'Aiello, A., Owen, D. H., Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E Gray, Thomas J Dilling, Joel...> ;Journal of Thoracic Oncology. 2024 Jan 24
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic...
Rodriguez-Abreu, D., Bosch-Barrera, J., Ahn, M., Johnson, M., Yu, X., Mohammad, S., Chen, X., Todd, T., Kim, J., Reck, M., Gray, J.> ;Clinical Lung Cancer. 2024 Jan 6
Osimertinibafatinib as first-line treatment for patients with metastatic non-small cell lung cancer with anexon 19 deletion or exon 21 L858R mutation.
Gilardone, S., Thapa, R., Laborde, J., Chen, D., Melzer, D., Pellini, B., Shafique, M., Saltos, A., Creelan, B., Tanvetyanon, T., Chiappori, A., Simon, G., Haura, E., ...> ;Journal of Thoracic Disease. 2023 Nov 30
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid B...
Jhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, Xiangning Huang, Alexander Kohlmann, Rachel Hodge, Yuri Rukazenkov, Juliann Chmielecki, Carin R Espenschied, Marti...> ;The Journal of Molecular Diagnostics. 2024 Jan 1
Race-inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?
Sonam Puri, Andreas N Saltos, Jhanelle E Gray> ;Cancer. 2023 Dec 1
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Riha Vaidya, Joseph M Unger, Lu Qian, Katherine Minichiello, Roy S Herbst, David R Gandara, Joel W Neal, Ticiana A Leal, Jyoti D Patel, Konstantin H Dragnev, Saiama N ...> ;JCO Precision Oncology. 2023 Sep 1
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Andreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, Alberto A Chiappori, Scott J Antonia, Michael R Shafique, Milijana Ugrenovic-Petrovic, Samer Sansil, Anthony Neuger...> ;Lung Cancer. 2023 Sep 1
21 citations
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
5 citations
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analy...
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita M...> ;Clinical Cancer Research. 2023 Sep 1
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander T...> ;Nature Communications. 2023 Jun 1
1 citations
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, N...> ;Clinical Cancer Research. 2023 Sep 15
1 citations
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.
Jhanelle E Gray, Hil Hsu, Diana Younan, Gaurav Suri, Victoria Chia, Alexander Spira, Melissa Johnson> ;Lung Cancer. 2023 Jul 1
1 citations
Goals and goal perceptions in patients with advanced stage lung cancer: a mixed methods study.
Kelly A Hyland, Laura B Oswald, Maija Reblin, Brent J Small, Jhanelle E Gray, Heather S L Jim, Paul B Jacobsen> ;Supportive Care in Cancer. 2023 May 1
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Dung-Tsa Chen, Andreas N Saltos, Trevor Rose, Zachary J Thompson, Ram Thapa, Alberto Chiappori, Jhanelle E Gray> ;Cancers. 2023 Apr 28
Qualitative Findings From a Survey on Patient Experiences and Satisfaction with Lung Cancer Screening.
Jaileene Pérez-Morales, Rashmi Pathak, Monica Reyes, Haley Tolbert, Rajwantee Tirbene, Jhanelle E Gray, Vani N Simmons, Matthew B Schabath, Gwendolyn P Quinn> ;Cancer Control. 2023 Mar 27
32 citations
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander T...> ;Nature Communications. 2023 Feb 27
64 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J Hochmair, Steven F Powell, Helge G Bischoff, Nir P...> ;Journal of Clinical Oncology. 2023 Apr 10
Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer.
Tawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray> ;Journal of Clinical Medicine. 2023 Feb 17
First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer.
Marjory Charlot, Jhanelle E Gray> ;JAMA Oncology. 2023 Mar 1
2 citations
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Sm...
Casey L Liveringhouse, Kujtim Latifi, Amalin G Asous, Nghi B Lam, Stephen A Rosenberg, Thomas J Dilling, Gretchen V MacMillan, Alberto A Chiappori, Eric B Haura, Ben C...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Jul 15
2 citations
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A...> ;Journal of the National Cancer Institute. 2023 Apr 11
Join now to see all

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Lectures

Lung Cancer—Non-Small Cell Metastatic
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
Three-year overall survival update from the PACIFIC trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

‘Astonishing’ 4-Year Survival in NSCLC with Pembro plus ChemoFebruary 4th, 2021
John Cleveland: How Moffitt Will Heal from Conflict of Interest Trauma—and from COVID-19May 29th, 2020
Adding Vorinostat May Improve Efficacy of Pembrolizumab in NSCLCSeptember 6th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida

Insurance Accepted

Aetna HMO
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment